Therapeutic Agents for Spine Injection

Published on 27/02/2015 by admin

Filed under Anesthesiology

Last modified 27/02/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1828 times

Chapter 2 Therapeutic Agents for Spine Injection

Local Anesthetics, Steroids, and Contrast Media

Chapter Overview

Chapter Synopsis: Spinal and epidural injections may be performed for therapeutic, diagnostic, and imaging purposes. This chapter explores the evolution of these techniques and the injectable agents in particular. Historically, the local anesthetic procaine was the most commonly injected drug followed by a wave of corticosteroid injection that began in the 1960s in Europe. Fluoroscopic guidance with injected dyes followed. Among local anesthetics, amide-type drugs have become the preferred class, which includes lidocaine and bupivacaine. Metabolism of the ester-type anesthetics (including procaine) produces para-aminobenzoic acid as a byproduct and presents greater risk of adverse allergic reaction. Local anesthetic systemic toxicity presents a separate serious complication risk. Glucocorticoids are useful in the control of pain because of their inhibitory action on inflammatory agents. Complication risks include Cushing’s syndrome—a suppression of the hypothalamic–pituitary–adrenal axis—and infarct from particulate steroids. Other more specific blockers of cytokines and other inflammatory mediators have also been investigated for epidural injection. Contrast media injected to aid in fluoroscopic imaging typically contain iodine. Adverse events are for the most part mild and easily treated. Anxiety can play a significant role in adverse reactions from injection of any substance.

Important Points:

Clinical Pearls:

Clinical Pitfalls:


Therapeutic spinal injections date back to the early part of the twentieth century before World War II. Over the past several decades, corticosteroids have emerged as the preferred class of spinally administered drugs for presumed inflammatory causes of pain. Common usage has been based largely on case series demonstrating efficacy and select double-blind placebo controlled trials (see Chapter 1). Surface landmark–based technique has also changed over time, with most authors currently endorsing very specific fluoroscopically controlled and contrast-proven injections. Despite these proscriptions, there have been no large-scale head-to-head trials that demonstrate outcome-based superiority of the more technologically advanced techniques. This chapter focuses on the agents that are commonly being used to perform therapeutic epidural and spinal injections, as well as the appropriate and safe use of contrast media (e.g., iohexol or gadodiamide agents) and some of the experimental agents being considered for future use.


One of the first reports of spinal injections for pain control was trans-sacral (caudal) injections of the local anesthetic procaine.1 The first use of epidural corticosteroids came out of the European literature.2 One of the first large series was published in 1961, in which Goebert and colleagues3 administered 121 injections to 113 patients spanning a 5-year period. The majority of these injections were caudal epidural injections with only three cervical epidural injections. Large-volume injections of a mixture of 1% procaine with 125 mg of hydrocortisone acetate in 30-mL volumes were administered over a consecutive 3-day period.3 Subsequently, in the modern era after the 1970s, interlaminar epidural injections became standard. Winnie and colleagues4 published recommendations that are still popular today, including corticosteroid dose limitations, 2-week dosing intervals, and three epidural procedures in series. Later, many physicians adopted a transforaminal fluoroscopically guided approach.

Local Anesthetics

Local anesthetics block voltage-gated sodium channels and interrupt propagation of axonal impulses, but their action is not only limited to those biological actions. There are two classes of local anesthetics based on structure–activity relationships: amino esters and amino amides. Because of the popularity and much more common use of amide-type local anesthetics for spinal diagnostic and therapeutic procedures, the focus of this review is mainly on the amide-type local anesthetics lidocaine and bupivacaine.5,6

Important properties of local anesthetics that pertain to clinical use include potency, speed of onset, and duration of action. The potency of a local anesthetic is related to its lipid solubility, which is usually defined by the octanol-buffer coefficient. The molecule must diffuse into the nerve membrane and bind at a partially hydrophobic site on the sodium channel.7 The more hydrophobic or lipophilic the local anesthetic, the more quickly it will permeate neuronal membranes, which increases its sodium channel binding affinity. Bupivacaine, for example, is many times more lipophilic than lidocaine (Table 2-1).

The speed of onset of most local anesthetics directly relates to the dissociation constant, or pKa, of the compound as well as the pH of the local tissues. The pKa is the pH at which half of the compound is ionized or protonated; the other half is in the un-ionized or neutral form that more readily crosses the nerve membrane. This makes the local anesthetic with the pKa that is closest to physiological pKa of faster onset. The pH of the local anesthetic preparation also affects the onset time, and some commercially available preparations containing a vasoconstrictor (e.g., epinephrine) have an adjusted pH that is acidic because of the addition of hydrochloric salts, enhancing the stability of the vasoconstrictor (Table 2-2).8,9 In vivo, other factors such as dose or concentration can also affect the onset of action.7 If faster onset is desired, then the addition of a small amount of sodium bicarbonate (1 : 20 NaHCO3-to-anesthetic volume) can help adjust the pH closer to physiological conditions. Caution should be taken not to adjust the pH greater than 7 because of the possibility that drug precipitation will increase.

Defining the duration of action is somewhat more difficult because it depends on multiple variables such as the location of injection, the lipophilicity of the local anesthetic, the dose, and the presence or absence of a vasoconstrictor. Longer acting local anesthetics are more lipophilic and are more slowly “washed out” from the lipophilic membrane.10 In humans, the peripheral vascular effects of the local anesthetics themselves also affect duration. Many agents have a biphasic effect on vascular smooth muscle with a vasoconstrictive response at low concentrations and vasodilatation at higher concentrations. These effects are complex and vary according to the concentration, time, and location of injection.7 In general, the more vascular the location, the more rapidly the agent is absorbed, metabolized, and excreted.

Metabolism of local anesthetics, not surprisingly, is dependent on its amide or ester structure. Ester type agents undergo rapid metabolism via plasma pseudocholinesterase, of which para-aminobenzoic acid (PABA) is a by-product. The ester type local anesthetics include procaine and benzocaine, which are two of the more commonly used agents. Conversely, amide-type agents such as lidocaine and bupivacaine are metabolized through the hepatic cytochrome P450 enzyme system as well as via conjugation. The byproduct of the ester-type metabolism, PABA, is thought to be an allergen involved in many local anesthetic allergic reactions. Moreover, given the dependence on the liver for the metabolism of amide-type local anesthetics, caution should be exercised when using these agents in patients with liver dysfunction.

Adverse Reactions

Reactions involving the use of local anesthetics can result from a number of different sources, including toxicity from the medication itself, a reaction to a preservative or added vasoconstrictor, or even an allergic reaction. Outside of the discussion of PABA as a potential allergen, immediate hypersensitivity reactions to amide local anesthetics and their pathomechanism remain largely unidentified. Clinically, the allergic response corresponds with anaphylaxis (manifesting as tachycardia; hypotension; and feelings of weakness, heat, or vertigo) even though immunologically mediated reactions have rarely been observed. Other ingredients in the local anesthetic commercial preparations such as certain preservatives or even anxiety need to be considered as potential sources of the adverse reaction as well.11

Toxicity, especially systemic toxicity, is usually the result of inadvertent intravascular injection, overdosage, or increased uptake from the area of injection. Systemic toxicity is a significant source of morbidity and mortality in the practice of anesthesia and especially the subspecialty regional anesthesia. Recently, the American Society of Regional Anesthesia and Pain Medicine published a practice advisory dealing with local anesthetic systemic toxicity (LAST). LAST was first recognized in the 1880s with the introduction of cocaine into clinical practice. Today, there is a focus on the development of less cardiotoxic local anesthetics based on structural changes or chirality (e.g., ropivacaine or levobupivacaine) as well as new and improved treatment for the cardiovascular effects of LAST with lipid emulsion therapy.

Epidemiological studies report a range of incidence of LAST that varies from 0 to 79 per 10,000.1214 In general, the cardiac toxicity results from the binding and inhibition of sodium channels, however, and correlates with local anesthetic potency especially in regards to inhibition of cardiac conduction. In addition, there is a vast array of other inotropic and metabolic signaling systems as well as mitochondrial metabolism implicated as potential targets for local anesthetics that would help explain the local anesthetic agents variable role in LAST.15

One way to reduce the incidence of LAST is to prevent it. Unfortunately, there is no single intervention that has proven to prevent this potentially life-threatening response. Obviously, using the least amount of local anesthetic required, incremental injection, frequent aspiration looking for the return of blood, using an intravascular marker such as epinephrine, and the use of ultrasound guidance are all recommended to try to prevent LAST.15

Classically, LAST presents in a predictable sequence with subjective central nervous system (CNS) symptoms of auditory changes, circumoral numbness, and metallic taste. Signs can then progress to seizures, coma, respiratory arrest, and ultimately cardiac toxicity that include cardiac excitation followed by cardiac depression at greatly increased blood concentrations. Unfortunately, in reality, the presentation can be extremely variable and is atypical in about 40% of cases with LAST. Even with an atypical presentation, the first symptoms presented in less than 5 minutes after injection 75% of the time. Seizure was the most common presenting symptom, and fewer than 20% of these seizures presented without any of the classic prodromal symptoms.15

Treatment of LAST, given the possible serious morbidity, should be quick and aggressive. Priorities include obtaining an airway, circulatory support, and diminishing the systemic effects as much as possible. Seizures should be rapidly treated with benzodiazepines if possible. Initiating the clinical algorithm as part of advanced cardiac life support (ACLS) is also important, although LAST presents a very different clinical scenario than that usually addressed by ACLS. The cause of circulatory arrest in LAST means that vasopressin and epinephrine may have less of a role or not be recommended. In fact, animal studies indicate that lipid emulsion treatment had better outcomes than both epinephrine and vasopressin.15,16 (Please refer to the Practice Advisory sheets included in Table 2-3.)

Table 2-3 Practice Advisory on Treatment of Local Anesthetic Systemic Toxicity for Patients Experiencing Signs or Symptoms of Local Anesthetic Systemic Toxicity

IV, intravenous; LAST, local anesthetic systemic toxicity.

Neal JM, Bernards CM, Butterworth JF IV, et al: ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med 35:152-161, 2010.


Cortisone as a purified glucocorticoid preparation was first introduced in 1949; later, in 1952, its application was described for epidural use.1719 Since then, the use of steroids has been applied in the field of interventional pain management with varying degrees of success and complications.

Glucocorticoids, of which the injectable corticosteroids are a part, are produced in the zona fasciculate of the adrenal cortex and function under negative feedback from the hypothalamus and pituitary gland as part of the hypothalamus–pituitary–adrenal axis.20 Glucocorticoids are used in interventional pain procedures because of their effects on inflammation. Glucocorticoids have significant inhibitory effects on cytokines and chemokines that are generated at sites of inflammation, as well as suppressive effects on leukocyte concentration, distribution, and function. Glucocorticoids have potential effects on most cells of the body through interactions with glucocorticoid receptors. Normally, intracellular glucocorticoid receptors are in a stabilized form coupled with two elements of heat-shock protein 90 (HSP90) and other proteins. Binding of glucocorticoid to its receptor allows the glucocorticoid to enter the cell where dissociation of the proteins occurs, and the glucocorticoid–receptor complex binds to the glucocorticoid response element of a target gene. Resultant transcription activity via RNA polymerase is thus altered, eventually leading to alterations in messenger RNA (mRNA) and new protein production, which leads to the hormonal response.21

Table 2-4 lists the antiinflammatory potency of some of the more commonly used neuraxial steroids.


Multiple complications of corticosteroids are possible and largely relate to unwanted side effects (e.g., iatrogenic Cushing’s syndrome). Tuel and colleagues22 described a case of iatrogenic Cushing’s syndrome occurring in a 24-year-old man after a single dose of 60 mg of methylprednisolone. Laboratory evidence of suppression of the hypothalamic–pituitary axis, 20-lb weight gain, and cushingoid features (moon facies, stria) persisted for 12 months. In another report, two doses of 80 mg of methylprednisolone resulted in Cushing’s syndrome with peripheral edema, moon facies, a “buffalo hump,” and purpura in a 63-year-old woman.23 These cases illustrate that doses that are well within the normal guidelines for epidural steroid injections may still result in adverse consequences.

Perhaps the most dreaded recent complications have been attributed to particulate steroids. A large survey of members of the American Pain Society24 identified 78 cases of either spinal cord or brainstem infarcts that were known of by those members that responded to the survey. Of these, 14 were fatal cases, and all involved particulate steroids. Tiso et al25 and Benzon, et al26 both studied the microscopic appearances of commonly used steroids. Although discrepancies exist between the two studies, they are useful to any discussion of the potential pathophysiology of injury. One notable difference is that dexamethasone was found to be nonparticulate in the study by Benzon et al26 (Fig. 2-1). A subsequent animal study demonstrated that dexamethasone acted like a nonparticulate in that direct, intentional injection of the vertebral artery in a porcine model resulted in ischemic brain injury only in the animals receiving particulate steroids.27

Although particulate size and aggregation have received much attention, other arguments exist regarding the etiology of steroid toxicity to the nervous system. One source of potential toxicity is the multiple chemical entities used in the formulation of epidural steroids, including benzyl alcohol, polyethylene glycol, and so on (Table 2-5). The ingredient with the most controversy is benzyl alcohol, which is used in Depo-Medrol, Aristocort, and Kenalog.20 Benzyl alcohol has been implicated in one case of flaccid paralysis of 16 months’ duration.28 Multiple other studies in different models on different steroids have been performed with variable results. Bogduk and Cherry,29 however, concluded that none of the literature provides direct evidence of the steroid itself or their preservatives causing neurotoxicity in the lumbar region.

Table 2-5 Chemical Entities Used in the Formulation of Epidural Steroids

Buy Membership for Anesthesiology Category to continue reading. Learn more here